OCS
OculisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The cash runway into 2H 2029 gives Oculis time to keep Privosegtor PIONEER and Licaminlimab PREDICT-1 alive; the DME miss is painful, but the retained retinal-thickness signal suggests the program still showed pharmacologic activity.
Posture
Defensive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bearish as of 2026-06-02.
What can break
Any delay or weak data in the remaining programs could re-open financing and dilution questions despite the current runway.
Momentum
39
Value
41
Sentiment
41
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $13.00 · Bull $21.00 · Bear $5.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bearish
Target $47.34
Why
Momentum39 · Δ7d -39.7
Value41 · Δ7d +0.1
Sentiment41 · Δ7d +64.6
So what
Weak posture (Net Bearish). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
39
34% active weight
Current posture
7d trendSoftening
Δ7d
-39.7
Δ21d
-35.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
41
33% active weight
Current posture
7d trendImproving
Δ7d
+64.6
Δ21d
+77.4
Why this grade
Composite grade D. Momentum 39.4 / Value 41.1 / Sentiment 41.4
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$829.53M
Beta
0.14
Shares Out
57.81M
P/E (TTM) · Derived
-4.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.69
Rev YoY
-
EPS YoY
+33.3%
Gross Margin
-
Op Margin
-
Net Debt
-$30.15M
Current Ratio
4.47
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology